GERON CORP Variable Lease, Cost
GERON CORP (GERN) reported Variable Lease, Cost of $285.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-02
- GERON CORP variable lease, cost for the quarter ending 2019-03-31 was $2.00K, a 91.67% decline year-over-year.
- GERON CORP variable lease, cost for the quarter ending 2018-03-31 was $24.00K.
- GERON CORP variable lease, cost for fiscal 2025 was $285.00K, a 9.20% increase from fiscal 2024.
- GERON CORP variable lease, cost for fiscal 2024 was $261.00K, a 24.13% decline from fiscal 2023.
- GERON CORP variable lease, cost for fiscal 2023 was $344.00K, a 10.97% increase from fiscal 2022.
- GERON CORP variable lease, cost for fiscal 2022 was $310.00K, a 23.02% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 12 month |
|---|---|---|
| 2025-12-31 | $285.00K 10-K · filed 2026-03-02 | |
| 2024-12-31 | $261.00K 10-K · filed 2026-03-02 | |
| 2023-12-31 | $344.00K 10-K · filed 2026-03-02 | |
| 2022-12-31 | $310.00K 10-K · filed 2025-02-27 | |
| 2021-12-31 | $252.00K 10-K · filed 2024-02-28 | |
| 2020-12-31 | $293.00K 10-K · filed 2023-03-16 | |
| 2019-12-31 | $17.00K 10-K · filed 2022-03-10 | |
| 2019-03-31 | $2.00K 10-Q · filed 2019-05-02 | |
| 2018-03-31 | $24.00K 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |